A5040579517- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Hematological disorders and diagnostics
- Hemoglobinopathies and Related Disorders
- Advanced biosensing and bioanalysis techniques
- Eosinophilic Disorders and Syndromes
- Hematopoietic Stem Cell Transplantation
- Viral-associated cancers and disorders
- Retinoids in leukemia and cellular processes
- Inflammatory Biomarkers in Disease Prognosis
- Molecular Biology Techniques and Applications
- Protein Degradation and Inhibitors
- Immunodeficiency and Autoimmune Disorders
- Chromosomal and Genetic Variations
- Cutaneous lymphoproliferative disorders research
- Neutropenia and Cancer Infections
- PI3K/AKT/mTOR signaling in cancer
- Cancer Mechanisms and Therapy
- Kruppel-like factors research
Nantes Université
2016-2023
Centre Hospitalier Universitaire de Nantes
2019-2023
Inserm
2023
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2023
Centre National de la Recherche Scientifique
2023
Laboratoire de Thermique et Energie de Nantes
2013-2022
Hôtel-Dieu de Paris
2017
Centre Hospitalier de Valenciennes
2011-2013
Groupe Hospitalier de l'Institut Catholique de Lille
2011
Hôpital Jeanne de Flandre
2008
Summary The diagnosis of myelodysplastic syndromes ( MDS ) is often challenging, time‐ and resource‐consuming. A thorough analysis complete blood count CBC parameters could, however, help to screen for among other causes cytopenia. To test this hypothesis, 109 newly‐diagnosed patients 399 cytopenic older than 50 years with confirmed absence were enrolled in a prospective study. Multiparametric highlighted three that significantly different between the two cohorts: mean corpuscular volume,...
Clonal chromosome abnormalities in Philadelphia-negative cells could concern chronic myeloid leukemia patients treated by tyrosine kinase inhibitors. The European LeukemiaNet distinguishes -7/del(7q) as a "warning". However, the impact of clonal abnormalities, and specifically those -7/del(7q), on clinical outcomes is unclear based case-reports showing morphological dysplasia increased risk acute leukemia, suggesting coexistence high-risk myelodysplastic syndrome. aim this study was to...
Abstract The aim of this study was to assess the potential impact kinetics serum levels seven cytokines during induction in acute myeloid leukemia (AML) patients. Indeed, role cytokines, pathophysiology and response therapy AML patients, remains under investigation. Here, we report on peripheral two Fms‐like tyrosine kinase 3 ligand (FL) interleukin‐6 (IL‐6), evaluated first‐line intensive induction. A new risk stratification can be proposed, which supersedes ELN 2017 classification predict...
In acute myeloid leukaemia (AML), interleukin-6 (IL-6) promotes chemo-resistance and its levels correlate with poor prognosis. IL-6 blockade may represent a promising therapeutic strategy. We aimed to test, tocilizumab, an anti-IL-6 receptor (R) monoclonal antibody in combination standard intensive AML induction chemotherapy.This investigator-initiated single-centre phase 1 trial was conducted at Nantes University Hospital France. According continual reassessment method, three escalating...
Next-generation sequencing (NGS) is used to investigate the presence of somatic mutations. The utility incorporating routine guide diagnosis and therapeutic decisions remains unclear. We report findings an observational, multicenter study that aimed assess impact mutation testing by NGS in a reallife setting chronic myeloid malignancies. A total 177 patients were enrolled, partitioned into two overlapping groups. In group (n=94), indication was search for clonal hematopoiesis, context...
Not available.
Abstract Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This however extremely heterogeneous in terms of molecular alterations. Moreover, course disease can vary greatly between indolent forms with slow progression and aggressive conditions rapidly pejorative. The identification early markers allowing to predict individual patients outcome has been unsuccessful so far. LyMa trial treated homogeneously cohort young...
The role of allogenic stem cell transplantation (ASCT) is still debated in myelofibrosis (MF).A retrospective analyzed was performed to compare the outcome 71 patients with intermediate-2 or high-risk Dynamic International Prognosis Scoring System+ (DIPSS+) primary (PMF) secondary (SMF) an indication ASCT as they ultimately underwent procedure (n=34) not (n=37).Five-year overall survival (OS) statistically different between both groups (allograft: 52% vs no allograft: 34%, P=.12). However,...
Abstract Multiple myeloma (MM) is still considered incurable and new therapeutic approaches are therefore needed. Deep‐sequencing analysis revealed the presence of BRAF mutations in up to 15% patients. The clinical experience ‐targeted therapy patients harboring mutation limited. We here report case a patient with penta‐refractory (bortezomib, lenalidomide, carfilzomib, pomalidomide, daratumumab) MM extramedullary BRAF‐mutated disease that achieved response dual MEK inhibition. At time...
Abstract Background Thanks to an improved therapeutic regimen in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), 5 year‐overall survival now exceeds 90%. Unfortunately, the 25% of children who relapse have initial poor prognosis, potentially driven by pre‐existing or emerging molecular anomalies. The latter are initially and essentially identified cytogenetics. However, some subtle alterations not visible through karyotyping. Methods Single nucleotide polymorphisms (SNP)...
A full-term new-born baby presented with nodular purple cutaneous lesions on the back, legs and face consistent a "blueberry muffin" rash (top left). He had no tumoural syndrome, thoracic or abdominal tumour infection. full blood count showed white cell of 37·71 × 109/l, haemoglobin concentration (Hb) 199 g/l, platelet 214 109/l monocyte 19·4 1·5% neutrophil precursors. Bone marrow (BM) aspiration disclosed 6% myeloid blasts, 17% promonocytes 36% monocytes right). Immunophenotyping...
Case report of a translocation : Dic(1;15)(p11;p11) as non-random abnormality in atypical MPD.
Case report of a translocation : Dic(1;15)(p11;p11) as non-random abnormality in essential thrombocytemia.